A study of off-target effects that sparked fear among investors of genome-editing companies receives methodological criticisms.

CRISPR Therapeutics, the company started by a pioneer of the gene editing technology, plans to raise $90 million from an initial public offering.

Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.

The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 

January was a profitable month for biotech companies going public, Burrill & Company says.

New model for neurodevelopment; more biotechs going public; how a virus jumped from mammals to birds; statin side effect linked to genetic variant

The drought has ended for biotech companies seeking to join the public market, but whether this upward swing will last is anybody’s guess.

Using evolutionary animal behavior theories, researchers find daytime stock traders’ strategies are maladapted.

Despite chill winds on Wall Street, investors continue to place bets on fledgling biotechnology companies.